Bionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
21 Agosto 2023 - 5:05PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it
has received a letter from the staff of the Listing Qualifications
department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the
Company that it has regained compliance with Nasdaq's minimum bid
price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for
continued listing on the Nasdaq Capital Market (the “Minimum Bid
Price Requirement”). As previously announced, the Company was
notified by Nasdaq on May 30, 2023 that it was not in compliance
with the Minimum Bid Price Requirement. The
notification letter noted that for the last 10 consecutive business
days, from August 7, 2023 to August 18, 2023, the
closing bid price of the Company's common stock has been
at $1.00 per share or greater, and thus the Company has
regained compliance with the Minimum Bid Price Requirement and the
matter is now closed.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information, visit www.bionano.com, www.bionanolaboratories.com or
www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024